Optimization for Chick Performance Bangkok, Thailand 12 th March 2013 Marcelo PANIAGO, DVM, MSc, MBA Director Global Veterinary Services - Poultry Ceva Santé Animale Libourne - France
Evolution of the poultry industry www.poultry.allotment.org.uk Protection against mortality www.bigdutchman.de Protection against mortality No post-vaccination reactions Reduction of shedding Easy to apply (hatcheries) No interference with MDA Long lasting immunity Cost effectiveness Etc etc etc
Evolution of the vaccines This early Chinese print shows a vaccination needle Edward Jenner Louis Pasteur Gaston Ramon Watson & Crick
Evolution of the vaccines EVOLUTION OF THE POULTRY VACCINES Less attenuated strains Mesogenic ND strains H-52 CEO ILT vaccines More reactive Less valences ND killed vaccine Safer vaccines Enterotropic ND strains Vector ILT or ND vaccines More convenient vaccines Evade MDA Application in the hatcheries Concentrated vaccines Concentrated ND killed vaccines More valences ND+IB+EDS+IC+SE killed vaccine Combinations Immune complex + vector ND vaccine
Evolution of the vaccines EVOLUTION OF THE POULTRY VACCINES First description of the disease Mesogenic strains, HB1 and LaSota strain Cloned ND vaccines Introduction of vector vaccines 1926 30 s 40 s 70 s 80 s 90 s 00 s First studies on attenuation of virulent NDV Thermo stable strains (V4 strain) Apathogenic enteric strains
63-00
Protection (%) Source: Bennejean et al., 1978 Interference % protection / challenge Live vaccines 100 90 80 70 60 50 40 30 20 10 Chickens Vaccinated Control With MDA Without 0 0 5 10 15 20 30 40 50 60 Age (days)
Protection (%) Source: Bennejean et al., 1978 Interference % protection / challenge Inactivated vaccines 100 90 80 70 60 50 40 30 20 10 Chickens Vaccinated Control With MDA Without 0 0 5 10 15 20 30 40 50 60 Age (days)
Live + Inactivated ND Vaccines INTERFERENCE WITH MDA % Protection 100 Control Live ND vaccine Inactivated ND vaccine 90 80 70 60 50 40 30 20 10 0 0 10 20 30 40 50 60 Age (days) Source: Bennejean et al., 1978
Live + Inactivated ND Vaccines INTERFERENCE WITH MDA % Protection 100 90 Control Live ND vaccine Inactivated ND vaccine Live + Inactivated ND vaccines 80 70 60 50 40 30 20 10 0 0 10 20 30 40 50 60 Age (days) Source: Bennejean et al., 1978
Immune complex IBD vaccine Winterfield 2512 Vaccine virus + Specific Antibodies (Virus Protecting Immunoglobulin) IBDV
How does it work? Day-old (0,1ml SQ) In-ovo (0,05 ml)
How does it work? Day-old (0,1ml SQ) In-ovo (0,05 ml)
Follicular Dendritic Cell (FDC) How does it work?
Individual Adjustment Y Y Bursa of Fabricius Bursa of Fabricius
Cell Associated Herpesvirus Marek s Disease (HVT) Cell to cell spread of herpesvirus MDV in nucleus R.L. Witter and K.A. Schat D.C. Johnson and J.D. Baines 19
Evading NDV Maternal Antibodies (MDA NDV ) Classical Live ND Vaccine rhvt-ndv NDV MΦ X MΦ MΦ Adapted from Moore-Dorsey, K. (2011)
Detection of vhvt-ndv vaccine virus in the spleen Vaccination positives/sampled % of positives D14 D21 D14 D21 vhvt-ndv 10/10 10/10 100% 100% vhvt-ndv & TRM 10/10 10/10 100% 100% Control 0/5 0/5 0% 0%
100% detection of vhvt-ndv in the spleen
Humoral immune response (HI) n.a. b b a b b a a a Positivity limit Different letters indicate statistically different groups!
100% detection of vhvt-ndv in the spleen No interference to ND HI immune response
Clinical protection against ND challenge (Malaysian genotype VII)
100% detection of vhvt-ndv in the spleen No interference to ND HI immune response No interference to ND protection vvndv challenge (Malaysian isolate Gen. VII)
Protection against ND shedding (Malaysian genotype VII) Challenge at week3 Challenge at week 6 b b a b b a a a a a b b a b b a a a a a Different letters indicate statistically different groups; positivity limit is shown with a red line No survivals in the control groups at 7 dpch after both challenges!
100% detection of vhvt-ndv in the spleen No interference to ND HI immune response No interference to ND protection vvndv challenge (Malaysian isolate Gen. VII) No interference to NDV shedding reduction
Protection against Marek s Disease Challenge at 8 days and lesions verification up to 76 days post challenge 82% 98% 30%
100% detection of vhvt-ndv in the spleen No interference to ND HI immune response No interference to ND protection vvndv challenge (Malaysian isolate Gen. VII) No interference to NDV shedding reduction No interference to MD protection RB1B challenge strain
Detection of Transmune take (histophatological bursal lesions) Bursa histology (% positives) Groups vhvt-ndv+trm (Marek diluent) TRM (PBS as diluent) D18 D21 D25 D28 D32 D35 0% 0% 40% 90% 100% 100% 0% 60% 70% 80% 90% 100%
100% detection of vhvt-ndv in the spleen No interference to ND HI immune response No interference to ND protection vvndv challenge (Malaysian isolate Gen. VII) No interference to NDV shedding reduction No interference to MD protection RB1B challenge strain No interference on Transmune take Bursa histopathological lesions
Optimization for Chick Performance Bangkok, Thailand 12 th March 2013 Marcelo PANIAGO, DVM, MSc, MBA Director Global Veterinary Services - Poultry Ceva Santé Animale Libourne - France
The future New vaccines, based on new technologies will progressively be part of our day to day vaccination programs. Vaccination in the hatchery will become the rule.
Hatchery equipment : DESVAC A company of the CEVA Group * DOVAC Day- old injection * Hatch sprayer cabinet * IMVAC * WINGVAC
In- ovo equipment ECAT In Ovo
Example of Ceva s offer
marcelo.paniago@ceva.com